The Hepatitis B Foundation has launched the first global registry of discrimination against people living with hepatitis B. <<Learn more here>>

Current Patient Opportunities

The Hepatitis B Foundation is pleased to share information about current and upcoming opportunities for people living with hepatitis B. These opportunities can be tools and resources, clinical trials, or other research opportunities to learn more from people who have hepatitis B.

 

ARCBanner2


 

BMS Graphic 3 V1 24Mar2022

The pharmaceutical company Bristol Myers Squibb (BMS) is now enrolling for two clinical trials in liver cancer (also called hepatocellular carcinoma or HCC). These trials have the reference numbers CA209-9DW and CA209-74W. If you are eligible and willing and able to take part, you will be helping to advance research. Eligible participants must be at least age 18 years old and diagnosed with liver cancer. These two trials are researching the safety and efficacy of new study drugs compared to a standard of care (CA209-74W) and to other standard drugs (CA209-9DW). Click here to learn more about full trial requirements, lists of tests and procedures used to determine trial eligibility, and more details about clinical trial participation in general.


 B Together Project SM Set FBIG 5

The company GlaxoSmithKline (GSK) is launching a new clinical trial, called B-Together, that will investigate how two study drugs (GSK3228836 and Pegasys) might work together to treat chronic hepatitis B (CHB). Researchers are hoping to find new potential treatments that could be more effective than those that are currently available and could lead to positive results that last long after the treatment ends. 

You may be eligible to participate in this trial if you are at least 18 years old, have been living with documented CHB for at least six months, and have also been receiving stable nucleos(t)ide treatment (not telbivudine) with no changes for at least six months prior to screening and no planned changes for the duration of the study (79 weeks). Individuals who have a current co-infection with or past history of hepatitis C virus, HIV or hepatitis D virus are not eligible to participate. This trial is ongoing in the UK, Spain, Russia, Poland, Italy, Korea, Japan, China, the US, Canada, and South Africa.

You can play a role in shaping your own health and the science of tomorrow! To learn more about this trial and check your eligibility to participate, visit https://btogetherstudy.com/.


 

Disclaimer – The opportunities listed on this page do not represent all available opportunities. The Hepatitis B Foundation receives funding to provide information about the specific opportunities listed on this page. The Hepatitis B Foundation follows IRB-approved protocols and our own Corporate Ethics Policy for all listings. If you are interested in having an opportunity listed on this page, please email info@hepb.org.